



# Pan American Health Organization



*Regional Office of the*  
World Health Organization

<http://www.paho.org>

## Forecasting for Pandemic Influenza and the Revolving Fund




# Objectives

- The Revolving Fund: Partnership between Countries and Suppliers
- Considerations for a Regional Pandemic Forecast
- Next steps?



# Growth of Revolving Fund and Introduction of New Vaccines, 1991-05




+ 2005 Estimated

# Building Blocks for Sustainable Vaccine Supply


## Strategic Alliances for Vaccines, Public-Private Partnerships

Vaccine	Supplier
MMR	Biomanghinos + GSK (2003)
Pentavalent	Butantan (DPT/Hep B) + Biomanghinos (Hib)
Yellow Fever	Biomanghinos + Rockefeller Foundation (1937)
Rotavirus	Butantan + NIH (2005)
Influenza	Butantan + Sanofi Pasteur (2000)

### Forecast Accuracy, MMR10, 2000-2005



# Revolving Fund: Promoting Partnerships



Pan American  
Health  
Organization

# Regional Pandemic Forecast Considerations

## Current Seasonal Situation

- 19 Countries purchasing influenza vaccine thru RF in 2006 – 8.9m doses
- Others like BOL, DOR, GUT, HAI, PER, & Caribbean consider inclusion in national schedules – 3m doses
- BRA, CHI, & MEX require 26.15m doses (68% of regional demand)

## Country Opportunities

- Optimize coverage levels during inter-pandemic periods
- Document best practices for influenza immunization, data collection, and analysis.
- Prepare infrastructure for distribution & adm. of vaccine in event of a pandemic
- Define minimum requirements for pandemic vaccine for priority groups

## Supplier Opportunities

- Increasing demand for seasonal vaccine drives production capacities
- Outline key principals for allocation of pandemic vaccine in equitable manner
- Accelerate technology transfer agreements with national labs.

**To: PANAMERICAN HEALTH ORGANIZATION  
Regional Office of the World Health Organization**

525 23<sup>rd</sup>. St. N.W. Washington, D.C. 20037, USA Tel: 202-974-3248 Fax 202-974-3635

**Family and Community  
Immunization Unit  
EPI Revolving Fund  
Estimated Requirements**

Country or Entity: \_\_\_\_\_

Calendar year: 2006

Activity: \_\_\_\_\_

## Requirements for Pandemic Influenza by Risk Group

	Population	Doses/ person	Total Doses	Avg. Estimated Cost/dose US \$	Total Cost US \$
1	Essential Services Personnel	2	0	\$3.5	\$0
2	People at higher risk of mortality from Influenza	2	0	\$3.5	\$0
3	Individuals in close contact with people at high risk	2	0	\$3.5	\$0
4	Preschool and elementary school children	2	0	\$3.5	\$0
5	People without risk factors for complications	2	0	\$3.5	\$0

### Definitions

- 1.- Personnel essential to maintain public services working, such as health workers, the police; firefighters, the armed forces, and the staff responsible for the operations of other public utilities
- 2.- Residents of nursing homes or long term care facilities, people aged 65 with chronic heart and lung disease, pregnant women in the second and third trimester, children aged 6-23 months, children aged 6 months to 18 years under a chronic aspirin regime, and other vulnerable groups such as indigenous people living in isolated communities
- 3.- Family members in daily contact with people at risk, and people in daily contact with children aged 0-5 months
- 4.- Children considered frequent transmitters of the disease in the community
- 5.- Includes healthy adults and children. The main objective is to lower the demand for medical services and enable individuals to continue with their daily activities and avoid greater social disruption.

### Assumptions

- a) 2 doses per person of Pandemic Influenza
- b) Aproximate cost of \$3.5/dosis
- c) The scale-up of groups will depend on vaccine availability

# Key Questions

- Characteristics of a Pandemic Vaccine (strain, quantity per dose, scheme, etc.)?
- Quantify available capacity and lead times for production?
- Presentation of the final product (prefill syringe, vial, aerosol)?
  - If the presentation is Vial, which would be the type of syringe to use in accordance with the required dose and if there is an alternative syringe?
- Logistical capacity of national cold chain and vaccine management?



# Next Steps?

- Continue to promote seasonal influenza uptake in the region:
  - VWA, April 2006
  - Unfinished Agenda Policy Seminar on Creating Fiscal Space, April 2006
  - TAG and ICC meetings, May 2006
  - Improve forecasting accuracy → expand production capacity
- Outline minimum requirements of pandemic vaccine for priority groups within national preparedness plans
- Clarify conditions for suppliers to increase capacity
- Promote strategic alliance for pandemic preparedness with suppliers
  - Technology transfer: Industry to strengthen existing arrangements and explore new ones
  - Clarify working arrangements for a pandemic
    - Bidding Process
    - Formula for allocation of limited supply to Americas
    - Balancing supply with country purchase orders – Revolving Fund



Follow-up meetings

Pan American  
Health  
Organization